Sun Pharma Advanced Research Company Limited has informed the Exchange regarding a press release dated February 03, 2026, titled "SPARC Announces Receipt of Priority Review Voucher associated with Sezaby® Approval".
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma Advanced Research Company (SPARC) has announced that it has received a Priority Review Voucher (PRV) from the US FDA in connection with the approval of Sezaby®, its drug for neonatal seizures. A PRV is a regulatory incentive awarded for developing treatments in areas such as rare pediatric diseases, rare diseases, or tropical diseases. The voucher entitles the holder to fast-track the FDA review of any future drug application or can be sold or transferred to another company, which has historically fetched significant value in the secondary market.
This is a positive development for SPARC shareholders. The PRV represents a potentially valuable asset that could be monetized through sale or used strategically to accelerate a future product's path to market, providing either non-dilutive revenue or a meaningful regulatory advantage.